Spots Global Cancer Trial Database for HA-WBRT vs SRS in Patients With Multiple Brain Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: HA-WBRT vs SRS in Patients With Multiple Brain Metastases

Official Title: Hippocampal Avoidance Whole Brain Radiotherapy (HA-WBRT) and Stereotactic Radiosurgery (SRS) in Patients With Multiple Brain Metastases

Study ID: NCT04277403

Conditions

Brain Metastases

Interventions

Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost

Single session or hypofractionated stereotactic radiosurgery

Study Description

Brief Summary: This study compares the effectiveness and safety of two radiation treatment techniques for patients with multiple brain metastases.

Detailed Description: For patients suffering from multiple brain metastases whole brain radiation therapy still constitutes a standard therapy. However, because of the risk of neurocognitive side effects as well as reduced local tumor control, employment of stereotactic radiosurgery (SRS) is becoming more common. The disadvantage of SRS alone may be poor intracranial tumor control because of frequent appearance of new distant brain metastases after therapy. In recent years hippocampal avoidance whole brain therapy has been shown to minimize treatment related side effects while reducing the rate of distant intracranial failure. In this study patients will be randomized to receive either hippocampal avoidance whole brain radiation therapy with integrated tumor boost (HA-WBRT+SIB) or stereotactic radiosurgery. The investigators hypothesize that HA-WBRT+SIB can improve intracranial tumor control compared to stereotactic radiosurgery, while avoiding additional neurocognitive side effects.